Bio Techne Company Top Insiders
| TECH Stock | USD 58.78 0.31 0.53% |
Bio Techne employs about 3.1 K people. The company is managed by 24 executives with a total tenure of roughly 42 years, averaging almost 1.0 years of service per executive, having 129.17 employees per reported executive. Assessment of Bio Techne's management performance can provide insight into the firm performance.
| Charles Kummeth CEO CEO and President and Director |
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
| 2025-05-28 | Ro Khanna | Acquired @ 47.93 | |||
| 2025-05-26 | April McClain Delaney | Disposed @ 46.78 | |||
| 2025-05-19 | Ro Khanna | Acquired @ 49.28 | |||
| 2025-04-29 | April McClain Delaney | Acquired @ 50.5 | |||
| 2025-04-09 | April McClain Delaney | Acquired @ 54.07 | |||
| 2025-04-08 | Robert Bresnahan, Jr. | Disposed @ 48.81 | |||
| 2025-04-01 | Julie Johnson | Disposed @ 57.35 | |||
| 2025-02-25 | Robert Bresnahan, Jr. | Acquired @ 64.22 | |||
| 2025-02-14 | Amy E Herr | Disposed 1860 @ 65.96 | View | ||
| 2025-01-27 | Kim Kelderman | Disposed 13392 @ 77.29 | View |
Monitoring Bio Techne's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Acquired vs Disposed
Filed vs Not Filed
Insider sentiment refers to the collective sentiment or feeling of Bio Techne's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Bio Techne Corp. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Bio Techne's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Bio Techne's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bio Techne's future performance. Based on our forecasts, it is anticipated that Bio will maintain a workforce of under 3100 employees by August 2025.Bio Techne's latest congressional trading
Congressional trading in companies like Bio Techne Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Bio Techne by those in governmental positions are based on the same information available to the general public.
| 2025-07-03 | Representative April Delaney | Acquired Under $15K | Verify | ||
| 2025-05-08 | Representative Rob Bresnahan | Acquired Under $15K | Verify | ||
| 2025-05-02 | Representative April Delaney | Acquired Under $15K | Verify |
Bio Techne Management Team Effectiveness
The company has return on total asset (ROA) of 0.0524 % which means that it generated a profit of $0.0524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0653 %, meaning that it created $0.0653 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Techne's current Return On Tangible Assets is estimated to increase to 0.16, while Return On Capital Employed is projected to decrease to 0.09. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 745.5 M, while Other Assets are projected to decrease to under 8.8 M.The Bio Techne's current Net Income Applicable To Common Shares is estimated to increase to about 344.5 M, while Common Stock Shares Outstanding is projected to decrease to under 169.2 M.
Bio Techne Workforce Comparison
Bio Techne Corp is rated fifth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 69,440. Bio Techne holds roughly 3,100 in number of employees claiming about 4% of equities under Health Care industry.
Bio Techne Profit Margins
The company has Profit Margin (PM) of 0.11 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.14 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.14.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.56 | 0.6 |
|
| |||||
| Net Profit Margin | 0.19 | 0.13 |
|
| |||||
| Operating Profit Margin | 0.26 | 0.16 |
|
| |||||
| Pretax Profit Margin | 0.27 | 0.14 |
|
| |||||
| Return On Assets | 0.0679 | 0.0715 |
|
| |||||
| Return On Equity | 0.0888 | 0.0934 |
|
|
Bio Techne Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bio Techne insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2025-09-01 | 0.5 | 2 | 4 | 84,308 | 160,890 |
| 2025-06-01 | 0.6 | 3 | 5 | 15,540 | 17,567 |
| 2025-03-01 | 0.8889 | 8 | 9 | 27,222 | 41,311 |
| 2024-12-01 | 3.8 | 19 | 5 | 97,489 | 35,246 |
| 2024-09-01 | 1.7143 | 24 | 14 | 480,195 | 219,267 |
| 2024-06-01 | 1.0 | 4 | 4 | 8,549 | 11,006 |
| 2024-03-01 | 3.5 | 7 | 2 | 127,860 | 11,511 |
| 2023-12-01 | 11.0 | 22 | 2 | 210,231 | 80,255 |
| 2023-09-01 | 2.3077 | 30 | 13 | 580,918 | 255,610 |
| 2023-06-01 | 0.6667 | 4 | 6 | 643,382 | 1,028,479 |
| 2023-03-01 | 0.1429 | 1 | 7 | 407,364 | 687,961 |
| 2022-12-01 | 6.0 | 18 | 3 | 17,874 | 15,700 |
| 2022-09-01 | 1.0526 | 20 | 19 | 502,817 | 295,508 |
| 2022-06-01 | 0.4 | 2 | 5 | 5,404 | 17,312 |
| 2022-03-01 | 2.6667 | 8 | 3 | 16,508 | 3,726 |
| 2021-12-01 | 0.8148 | 22 | 27 | 44,758 | 78,245 |
| 2021-09-01 | 0.5075 | 34 | 67 | 287,899 | 284,983 |
| 2021-06-01 | 0.1429 | 3 | 21 | 48,458 | 102,196 |
| 2021-03-01 | 0.3214 | 9 | 28 | 109,930 | 192,003 |
| 2020-12-01 | 0.5472 | 29 | 53 | 104,059 | 189,976 |
| 2020-09-01 | 1.1111 | 30 | 27 | 355,299 | 112,119 |
| 2020-06-01 | 0.3824 | 13 | 34 | 82,659 | 155,110 |
| 2020-03-01 | 0.2857 | 4 | 14 | 43,118 | 87,623 |
| 2019-12-01 | 0.875 | 28 | 32 | 105,187 | 164,217 |
| 2019-09-01 | 1.8125 | 29 | 16 | 410,704 | 145,429 |
| 2019-06-01 | 0.8571 | 6 | 7 | 77,467 | 56,028 |
| 2018-09-01 | 0.9583 | 23 | 24 | 338,083 | 105,331 |
| 2018-06-01 | 1.5 | 3 | 2 | 15,000 | 9,136 |
| 2018-03-01 | 0.3333 | 1 | 3 | 5,000 | 10,000 |
| 2017-12-01 | 13.0 | 39 | 3 | 459,392 | 10,100 |
| 2017-09-01 | 0.2857 | 2 | 7 | 76,097 | 2,483 |
| 2017-06-01 | 0.2222 | 2 | 9 | 10,000 | 21,359 |
| 2017-03-01 | 0.125 | 1 | 8 | 1,667 | 86,100 |
| 2016-12-01 | 4.0 | 16 | 4 | 39,192 | 1,300 |
| 2016-09-01 | 1.9333 | 29 | 15 | 571,372 | 23,643 |
| 2016-06-01 | 0.1667 | 1 | 6 | 5,000 | 10,800 |
| 2016-03-01 | 0.4286 | 3 | 7 | 16,666 | 27,322 |
| 2015-09-01 | 5.7143 | 40 | 7 | 451,536 | 22,475 |
| 2015-06-01 | 0.3333 | 1 | 3 | 385.00 | 1,694 |
| 2015-03-01 | 0.6 | 3 | 5 | 8,166 | 13,732 |
| 2014-12-01 | 3.0 | 21 | 7 | 53,591 | 11,182 |
| 2014-09-01 | 4.0 | 12 | 3 | 219,089 | 15,000 |
| 2014-06-01 | 2.2 | 11 | 5 | 112,181 | 9,907 |
| 2014-03-01 | 0.625 | 5 | 8 | 25,000 | 50,000 |
| 2013-12-01 | 2.3 | 23 | 10 | 75,000 | 70,000 |
| 2013-09-01 | 1.75 | 7 | 4 | 85,567 | 5,712 |
| 2012-12-01 | 2.75 | 11 | 4 | 61,012 | 34,012 |
| 2012-09-01 | 1.3333 | 4 | 3 | 3,753 | 1,376 |
| 2012-03-01 | 0.4 | 4 | 10 | 6,385,056 | 15,162,189 |
| 2011-12-01 | 3.3333 | 10 | 3 | 43,000 | 32,350 |
| 2011-06-01 | 0.5385 | 7 | 13 | 20,505 | 47,650 |
| 2010-12-01 | 1.3333 | 12 | 9 | 68,000 | 55,031 |
| 2010-09-01 | 1.0 | 4 | 4 | 14,034 | 21,039 |
| 2009-12-01 | 7.0 | 7 | 1 | 35,000 | 2,000 |
| 2009-06-01 | 0.6667 | 2 | 3 | 10,785 | 3,893 |
| 2008-12-01 | 8.0 | 8 | 1 | 35,500 | 2,000 |
| 2008-09-01 | 0.8571 | 6 | 7 | 17,981 | 31,000 |
| 2008-06-01 | 0.3333 | 1 | 3 | 748.00 | 1,078 |
| 2007-12-01 | 2.6667 | 8 | 3 | 38,500 | 9,000 |
| 2007-09-01 | 0.6 | 6 | 10 | 21,293 | 47,000 |
| 2007-06-01 | 0.375 | 3 | 8 | 15,000 | 69,190 |
| 2006-12-01 | 6.0 | 6 | 1 | 30,000 | 50,000 |
| 2006-06-01 | 0.5 | 1 | 2 | 1,498 | 1,498 |
| 2006-03-01 | 0.4 | 10 | 25 | 457,500 | 582,180 |
| 2005-09-01 | 0.7333 | 11 | 15 | 83,637 | 185,984 |
| 2005-06-01 | 0.5 | 7 | 14 | 79,142 | 158,284 |
| 2005-03-01 | 1.0 | 1 | 1 | 1,000.00 | 1,425 |
| 2004-12-01 | 7.0 | 7 | 1 | 50,000 | 0.00 |
| 2004-09-01 | 0.8125 | 13 | 16 | 32,277 | 41,075 |
| 2004-06-01 | 0.3333 | 1 | 3 | 40,000 | 80,000 |
| 2003-12-01 | 3.0 | 12 | 4 | 73,334 | 130,000 |
| 2003-09-01 | 0.6923 | 9 | 13 | 97,846 | 166,876 |
Bio Techne Notable Stakeholders
A Bio Techne stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bio Techne often face trade-offs trying to please all of them. Bio Techne's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bio Techne's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Charles Kummeth | CEO and President and Director | Profile | |
| MD MBA | President Genomics | Profile | |
| William Geist | President Segment | Profile | |
| James CPA | Executive CFO | Profile | |
| James Hippel | CFO and VP of Fin. | Profile | |
| Gary Latham | VP CTO | Profile | |
| Robert Gavin | Sr. VP of Protein Platforms Division | Profile | |
| Shane Bohnen | General VP | Profile | |
| Lynne Hohlfeld | Senior Division | Profile | |
| Luca Cicchetti | Managing Director | Profile | |
| Brenda JD | Gen VP | Profile | |
| Martin Wirtz | Senior Development | Profile | |
| Cheryl Bethune | Senior Officer | Profile | |
| David CFA | Senior Development | Profile | |
| Gerry Andros | Vice Marketing | Profile | |
| Bernie Andruss | Senior Division | Profile | |
| Kim Kelderman | Pres Genomics | Profile | |
| Evett Kruka | Senior Division | Profile | |
| Dylan Malayter | Senior Division | Profile | |
| David Clair | IR Contact Officer | Profile | |
| Kevin Smyth | Senior Officer | Profile | |
| Steven Silverman | Senior Experience | Profile | |
| Brenda Everson | Senior Officer | Profile | |
| Steve Crouse | Senior Division | Profile |
About Bio Techne Management Performance
The success or failure of an entity such as Bio Techne Corp often depends on how effective the management is. Bio Techne management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.16 | |
| Return On Capital Employed | 0.09 | 0.09 | |
| Return On Assets | 0.07 | 0.07 | |
| Return On Equity | 0.09 | 0.09 |
Bio Techne Workforce Analysis
Traditionally, organizations such as Bio Techne use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bio Techne within its industry.Bio Techne Manpower Efficiency
Return on Bio Techne Manpower
| Revenue Per Employee | 373.9K | |
| Revenue Per Executive | 48.3M | |
| Net Income Per Employee | 54.2K | |
| Net Income Per Executive | 7M | |
| Working Capital Per Employee | 147.8K | |
| Working Capital Per Executive | 19.1M |
Complementary Tools for Bio Stock analysis
When running Bio Techne's price analysis, check to measure Bio Techne's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Techne is operating at the current time. Most of Bio Techne's value examination focuses on studying past and present price action to predict the probability of Bio Techne's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Techne's price. Additionally, you may evaluate how the addition of Bio Techne to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |